Your browser doesn't support javascript.
loading
Whole blood transcriptome in long-COVID patients reveals association with lung function and immune response.
Blankestijn, Jelle M; Baalbaki, Nadia; Bazdar, Somayeh; Beekers, Inés; Beijers, Rosanne J H C G; van den Bergh, Joop P; Bloemsma, Lizan D; Cornelissen, Merel E B; Dekker, Tamara; Duitman, Jan Willem; Houweling, Laura; Jacobs, John J L; van der Lee, Ivo; Linders, Paulien M A; Noij, Lieke C E; Nossent, Esther J; van de Pol, Marianne A; Sondermeijer, Brigitte M; Geelhoed, J J Miranda; Weersink, Els J M; Golebski, Korneliusz; Abdel-Aziz, Mahmoud I; Maitland-van der Zee, Anke H.
Afiliação
  • Blankestijn JM; Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands; Amsterdam Public Health, Amsterdam, The Netherlands. Electronic address: j.m.blankestijn@amsterdamumc.nl.
  • Baalbaki N; Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands; Amsterdam Public Health, Amsterdam, The Netherlands.
  • Bazdar S; Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands; Amsterdam Public Health, Amsterdam, The Netherlands.
  • Beekers I; Department of Health, Ortec B.V., Zoetermeer, The Netherlands.
  • Beijers RJHCG; Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, The Netherlands.
  • van den Bergh JP; School of Nutrition and Translational Research in Metabolism, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands; Department of Internal Medicine, VieCuri Medical Center, Venlo, The Netherlands.
  • Bloemsma LD; Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands; Amsterdam Public Health, Amsterdam, The Netherlands.
  • Cornelissen MEB; Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands; Amsterdam Public Health, Amsterdam, The Netherlands.
  • Dekker T; Experimental Immunology (EXIM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Duitman JW; Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Experimental Immunology (EXIM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Houweling L; Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Department of Environmental Epidemiology, Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands.
  • Jacobs JJL; Department of Health, Ortec B.V., Zoetermeer, The Netherlands.
  • van der Lee I; Department of Pulmonology, Spaarne Hospital, Hoofddorp, The Netherlands.
  • Linders PMA; Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Noij LCE; Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands; Amsterdam Public Health, Amsterdam, The Netherlands.
  • Nossent EJ; Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • van de Pol MA; Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Sondermeijer BM; Department of Pulmonology, Spaarne Hospital, Hoofddorp, The Netherlands.
  • Geelhoed JJM; Department of Respiratory Medicine, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
  • Weersink EJM; Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Golebski K; Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.
  • Abdel-Aziz MI; Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands; Amsterdam Public Health, Amsterdam, The Netherlands; Department of Clinical Pharmacy, Faculty of Pharmacy, Assiut Universi
  • Maitland-van der Zee AH; Department of Pulmonary Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands; Amsterdam Public Health, Amsterdam, The Netherlands; Department of Pediatric Respiratory Medicine, Emma Children's Hospita
Article em En | MEDLINE | ID: mdl-38830512
ABSTRACT

BACKGROUND:

Months after infection with severe acute respiratory syndrome coronavirus 2, at least 10% of patients still experience complaints. Long-COVID (coronavirus disease 2019) is a heterogeneous disease, and clustering efforts revealed multiple phenotypes on a clinical level. However, the molecular pathways underlying long-COVID phenotypes are still poorly understood.

OBJECTIVES:

We sought to cluster patients according to their blood transcriptomes and uncover the pathways underlying their disease.

METHODS:

Blood was collected from 77 patients with long-COVID from the Precision Medicine for more Oxygen (P4O2) COVID-19 study. Unsupervised hierarchical clustering was performed on the whole blood transcriptome. These clusters were analyzed for differences in clinical features, pulmonary function tests, and gene ontology term enrichment.

RESULTS:

Clustering revealed 2 distinct clusters on a transcriptome level. Compared with cluster 2 (n = 65), patients in cluster 1 (n = 12) showed a higher rate of preexisting cardiovascular disease (58% vs 22%), higher prevalence of gastrointestinal symptoms (58% vs 29%), shorter hospital duration during severe acute respiratory syndrome coronavirus 2 infection (median, 3 vs 8 days), lower FEV1/forced vital capacity (72% vs 81%), and lower diffusion capacity of the lung for carbon monoxide (68% vs 85% predicted). Gene ontology term enrichment analysis revealed upregulation of genes involved in the antiviral innate immune response in cluster 1, whereas genes involved with the adaptive immune response were upregulated in cluster 2.

CONCLUSIONS:

This study provides a start in uncovering the pathophysiological mechanisms underlying long-COVID. Further research is required to unravel why the immune response is different in these clusters, and to identify potential therapeutic targets to create an optimized treatment or monitoring strategy for the individual long-COVID patient.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article